Showing 541 - 560 results of 118,116 for search '(( 5 ((nn decrease) OR (a decrease)) ) OR ( a ((non decrease) OR (fold decrease)) ))', query time: 1.71s Refine Results
  1. 541
  2. 542

    Data Sheet 1_Regulation of SLC7A11 by LncRNA GPRC5D-AS1 mediates ferroptosis in skeletal muscle: Mechanistic exploration of sarcopenia.pdf by Wei Gong (112494)

    Published 2025
    “…This study investigates the role of the long non-coding RNA GPRC5D-AS1 in the development and progression of sarcopenia through its regulation of SLC7A11. …”
  3. 543

    Supplementary file 1_Regulation of SLC7A11 by LncRNA GPRC5D-AS1 mediates ferroptosis in skeletal muscle: Mechanistic exploration of sarcopenia.pdf by Wei Gong (112494)

    Published 2025
    “…This study investigates the role of the long non-coding RNA GPRC5D-AS1 in the development and progression of sarcopenia through its regulation of SLC7A11. …”
  4. 544
  5. 545

    Influence of Acidic pH on Hydrogen and Acetate Production by an Electrosynthetic Microbiome by Edward V. LaBelle (608387)

    Published 2014
    “…Cyclic voltammetry revealed a 250 mV decrease in hydrogen overpotential and a maximum current density of 12.2 mA/cm<sup>2</sup> at −765 mV (0.065 mA/cm<sup>2</sup> sterile control at −800 mV) by the <i>Acetobacterium</i>-dominated community. …”
  6. 546
  7. 547
  8. 548
  9. 549
  10. 550

    Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2‑Aminoquinoline Inhibitors by Maris A. Cinelli (1309419)

    Published 2017
    “…We previously developed a class of membrane-permeable 2-aminoquinoline inhibitors and later rearranged the scaffold to decrease off-target binding. …”
  11. 551

    HRMECs treated with SUZ12 siRNA demonstrate increased miR-200b expression, decreased VEGF expression and decreased endothelial branching. by Michael Anthony Ruiz (726055)

    Published 2015
    “…However, transfection of SUZ12 siRNA significantly reduced endothelial branching compared to HG+control siRNA. [NG+control siRNA = 5mM D-glucose + 100nM control siRNA, HG+control siRNA = 25mM D-glucose + 100nM control siRNA, HG+EZH2 siRNA = 25mM D-glucose + 100nM EZH2 siRNA, HG+SUZ12 siRNA = 25mM + 100nM SUZ12 siRNA; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to U6 or β-actin and expressed as a fold change of NG+control siRNA].…”
  12. 552
  13. 553
  14. 554
  15. 555
  16. 556

    Heparin (GAG-hed) inhibits LCR activity of Human Papillomavirus type 18 by decreasing AP1 binding-5 by Rita Villanueva (65963)

    Published 2011
    “…Nuclear extracts obtained from HeLa cells were exposed to GAG-hed at indicated concentrations for 10 min before labelled probe addition (Panels B and D). On panel A and C, complex specificity is denoted by competition assays with a 100 fold excess of indicated oligonucleotide competitor. …”
  17. 557

    A summary of the included study characteristics. by Zahra Tajik (20752452)

    Published 2025
    “…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  18. 558
  19. 559
  20. 560